BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC

Reuters

Feb 20

Feb 19 (Reuters) - Bicara Therapeutics Inc BCAX.O:

FICERAFUSP ALFA 2000MG Q2W DEMONSTRATES DEEP, DURABLE RESPONSES IN 1L R/M HPV-NEGATIVE HNSCC AND SUPPORTS DEVELOPMENT OF LESS FREQUENT DOSING REGIMEN
BICARA THERAPEUTICS INC: PLANS TO DEVELOP A LOADING AND EVERY-THREE-WEEK MAINTENANCE REGIMEN FOR FICERAFUSP ALFA, PENDING REGULATORY ALIGNMENT

Source text: ID:nGNX7kDHsZ

Further company coverage: BCAX.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612397192"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612397192\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612397192?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 06:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612397192","market":"us","top_or_hot":-1,"title":"BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC</title></head><body><p><span>Feb 19 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/BCAX\">Bicara Therapeutics</a> Inc <span>BCAX.O</span>:</p><ul><li><p>FICERAFUSP ALFA 2000MG Q2W DEMONSTRATES DEEP, DURABLE RESPONSES IN 1L R/M HPV-NEGATIVE HNSCC AND SUPPORTS DEVELOPMENT OF LESS FREQUENT DOSING REGIMEN</p></li><li><p>BICARA THERAPEUTICS INC:  PLANS TO DEVELOP A LOADING AND EVERY-THREE-WEEK MAINTENANCE REGIMEN FOR FICERAFUSP ALFA, PENDING REGULATORY ALIGNMENT</p></li></ul><p>Source text: <span>ID:nGNX7kDHsZ</span></p><p>Further company coverage: <span>BCAX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-20 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC</title></head><body><p><span>Feb 19 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/BCAX\">Bicara Therapeutics</a> Inc <span>BCAX.O</span>:</p><ul><li><p>FICERAFUSP ALFA 2000MG Q2W DEMONSTRATES DEEP, DURABLE RESPONSES IN 1L R/M HPV-NEGATIVE HNSCC AND SUPPORTS DEVELOPMENT OF LESS FREQUENT DOSING REGIMEN</p></li><li><p>BICARA THERAPEUTICS INC:  PLANS TO DEVELOP A LOADING AND EVERY-THREE-WEEK MAINTENANCE REGIMEN FOR FICERAFUSP ALFA, PENDING REGULATORY ALIGNMENT</p></li></ul><p>Source text: <span>ID:nGNX7kDHsZ</span></p><p>Further company coverage: <span>BCAX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCAX","symbol_name":"Bicara Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF1CF:1","article_id":"2612397192","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612397192","pubTimestamp":1771541172,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCCFeb 19 (Reuters) - Bicara Therapeutics Inc BCAX.O:FICERAFUSP ALFA 2000MG Q2W DEMONSTRATES DEEP, DURABL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCAX":"Bicara Therapeutics","BK4139":"生物科技"},"translate_title":"简介-Ficerafusp Alfa 2000mg Q2W在1L R/M HPV阴性HNSCC中显示出深度、持久的应答","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAX":0.9},"content_text":"BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCCFeb 19 (Reuters) - Bicara Therapeutics Inc BCAX.O:FICERAFUSP ALFA 2000MG Q2W DEMONSTRATES DEEP, DURABLE RESPONSES IN 1L R/M HPV-NEGATIVE HNSCC AND SUPPORTS DEVELOPMENT OF LESS FREQUENT DOSING REGIMENBICARA THERAPEUTICS INC:  PLANS TO DEVELOP A LOADING AND EVERY-THREE-WEEK MAINTENANCE REGIMEN FOR FICERAFUSP ALFA, PENDING REGULATORY ALIGNMENTSource text: ID:nGNX7kDHsZFurther company coverage: BCAX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}